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 Abstract 
Randomised controlled trials provide the most rigorous test of efficacy and effectiveness for 
interventions used in healthcare. They underpin much of clinical practice, yet older people are often 
excluded from studies, resulting in uncertainty about risks and benefits of new treatments. 
 
Encouraging inclusion of older people in randomised controlled trials and reporting of trial results in 
a rigorous manner is a key function of clinical geriatrics journals such as Age and Ageing. This article 
provides practical advice on how to report randomised controlled trials that are targeted at older 
people.  Some of these issues are generic, but there are specific requirements which apply to most 
studies of older people. Recording and reporting basic characteristics of recruits in terms of physical 
function, cognition, co-morbidity and / or frailty is vital to allow proper interpretation of the external 
validity of the trial.  Adverse effects should include consideration of common geriatric problems 
including falls. 
 
Authors should follow the CONSORT reporting guidelines (CONsolidated Standards Of Reporting Trials) 
to enhance the transparency and quality of their manuscript. 
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Key points 
 Encouraging inclusion of older people in randomised controlled trials and reporting of trial 
results is a key function of clinical geriatrics journals such as Age and Ageing. 
 This article gives advice on manuscript preparation, which if followed, should enhance the 
clinical impact of the research, and minimise the risk of research waste. 
 Age and Ageing follows the recommendations of the International Committee of Medical 
Journal Editors (ICMJE), which requires registration of clinical trials in a public trials registry. 
 It is recommended that authors follow the CONSORT reporting guidelines in their 
manuscript preparation. 
   
Background 
Randomised controlled trials provide the most rigorous test of efficacy and effectiveness for the 
interventions used in healthcare. They underpin much of clinical practice and many  guidelines, yet 
older people (and particularly those who are frail or carry high levels of co-morbidity) are often 
excluded from studies 1, resulting in uncertainty about risks and benefits of new treatments for older 
people 2. 
 
Encouraging inclusion of older people in randomised controlled trials and reporting of trial results is 
therefore a key function of clinical geriatrics journals such as Age and Ageing. This article gives advice, 
which if followed, should enhance the clinical impact of the research, and minimise the risk of research 
waste 3. Some of these issues are generic, but there are also specific reporting requirements which 
apply to most trials for older people. This article provides practical advice on how to report 
randomised controlled trials that are targeted at this sector of the population. However manuscript 
preparation and reporting does not however occur as an isolated activity; the advice that is provided 
is relevant to the whole process of trial conduct, from conception to design, running of the study and 
analysis. 
 
General points 
Writing a high-quality clinical trial report is much easier if the study has been well designed; this 
includes recruitment of an appropriate number of participants, low dropout rate, use of clinically 
relevant outcomes and a well-structured, pre-determined analysis plan. The best writing cannot 
rescue a poorly-designed trial. Thus the process of producing a high-quality report starts at the point 
of conceiving the need for the trial. It is also useful perhaps to consider some of the issues that lead 
to rejection of manuscripts: 
 
- Is the study question important to patients, carers and to clinicians? Age and Ageing is a 
clinical journal, and so we expect the trial outcome to be clinically relevant. 
- Was the trial registered prospectively on a recognised trials database? e.g. 
https://clinicaltrials.gov.  
Box 1. 
Age and Ageing follows the recommendations of the International Committee of Medical 
Journal Editors (ICMJE), which requires registration of clinical trials in a public trials registry 
at or before the time of first patient enrolment as a condition of consideration for 
publication (see http://www.icmje.org/recommendations). 
 
- Is there a clearly stated primary outcome? 
- Is the study adequately powered for the primary outcome? 
- If it is possible to blind (mask) participants and researchers to the trial intervention, has this 
been done, and are the methods adequate? 
- Was the randomisation process adequate, and was allocation concealment preserved? 
- Is sufficient information provided on the patient cohort to allow the reader to judge external 
validity and relevance of the findings? 
- Is the study population appropriate to the research question? 
- Are the outcomes analysed as set out at the start of the trial in a pre-defined statistical analysis 
plan? 
 
Practice in the conduct and reporting of trials has been substantially improved by methodological 
initiatives such as CONSORT (CONsolidated Standards Of Reporting Trials) 4 and its various extensions 
(available through the EQUATOR network: Enhancing the Quality and Transparency Of health 
Research; http://www.equator-network.org/). Completion of the CONSORT checklist and submission 
as a supplementary file is encouraged, as this demonstrates explicitly that the trial report follows the 
guidelines.  
 
Box 2. 
Age and Ageing recommends that authors follow the CONSORT reporting guidelines 4  
(available through the EQUATOR network: Enhancing the Quality and Transparency Of 
health Research; http://www.equator-network.org/).  
Completion of the CONSORT checklist and submission as a supplementary file is 
encouraged.  
 
Whilst any trial design involves compromises, and there is no such thing as a perfect study, the issues 
highlighted above are inherent to the design of a good trial. As such, they cannot be remedied at the 
stage of writing the trial report. Some other issues are important and are covered in the sections 
below, but will not necessarily lead to rejection on their own – often because they can be remedied 
at the writing stage. These include results presented in a way that is difficult to understand, discussion 
not covering areas recommended by the CONSORT statement, or conclusions not being supported by 
the data. 
 
Specific sections of the paper: 
The abstract 
Providing a clear well written abstract to accompany the paper (or for conference proceedings) is vital. 
The CONSORT extension on abstracts is highly recommended 5 ; it gives a list of essential items that 
should be considered. Authors should be mindful that often the abstract is the only part of the full 
paper that is read, and so it is essential that this summary of the work is both clear and accurate.   
 
 
The Introduction 
Every paper tells a story, and the introduction is where the story starts. The author should use the 
introduction to make three things clear. Firstly, why is the issue important? Secondly, what evidence 
already exists – eg are there published pilot data or a systematic review that provides initial evidence 
of possible efficacy? Thirdly, what is the gap that this trial aims to fill – or in other words what is the 
uncertainty that the trial aims to address? Readers of Age and Ageing are generally aware that the 
number of older people in the world is increasing and that there is a need to find better methods of 
care; therefore it is not necessary to state these very general points. 
 
The Methods 
With the advent of on-line supplementary information in journals, including Age and Ageing, there is 
no excuse for incomplete methods. The information critical to telling the story of the paper should be 
included in the main text, but additional detail can be put into supplementary information. Some key 
issues that are important in the methods section are listed below, using the PICO format: 
 
Population: Tell the reader who you recruited (inclusion and exclusion criteria), where you recruited 
the participants from, and how you recruited them. Justify why you used exclusion criteria; was it 
because of safety, targeting a group most likely to benefit, or because of inability to perform certain 
outcomes? 
 
Intervention: Sufficient detail is required so that the intervention can be replicated. This is 
straightforward for most pharmacological interventions, but requires more information for complex 
interventions such as exercise programmes. Consider describing the intervention in detail in 
supplementary (on-line only) material, and also consider providing links to any relevant manuals, 
which should be publicly available. 
 
Comparator: If usual care is the comparator, describe what this comprises. Age and Ageing is an 
international journal, and many readers may be unfamiliar with how health services work in the 
country that hosted your trial. Understanding the setting and processes of usual care is essential to 
judge generalisability. 
 
Outcomes: The method for collecting or measuring each outcome should be described in sufficient 
detail for others to be able to replicate. Justification for the choice of outcomes is needed; this 
justification should include reference to the original methods paper and evidence of validation of the 
method, ideally in a relevant population of older people. State what the primary outcome is; this 
should have been decided before the start of the trial. Note that there usually should be only one 
primary outcome; if two outcomes are nominated as co-primary outcomes, this should be stated 
explicitly and should be reflected in how the sample size calculation is constructed (usually by splitting 
the alpha in the sample size calculation). Offering multiple primary outcomes is strongly discouraged. 
 
Randomisation and blinding: The method used for randomisation should be described in detail; it is 
not sufficient to merely state that randomisation took place. What method was used – computer 
generated lists, pre-prepared envelopes, web or telephone based interactive randomisation systems?  
Sequence generation, allocation concealment and mechanism of implementation should all be 
covered. The key issue here is to give sufficient detail to reassure readers that the process was robust 
and unlikely to be subject to manipulation. Using web or telephone based systems run by a third party 
not otherwise involved in the conduct of the trial is preferable to other methods for this reason. 
 
Similarly, for blinding (or ‘masking’), authors should be explicit about who is blinded. Participants? 
Researchers measuring outcomes? Supporting clinical staff? Blinding of researchers can almost always 
be employed for outcome measures even if other aspects are harder to blind. When blinding is used, 
how successful was the blinding? Giving some data to support this (e.g. a description of whether the 
research team measuring outcomes could guess group allocation) gives reassurance to readers that 
the blinding process did work.  
 
Analysis: Include a sample size calculation, which should have been done before the start of the trial. 
Sample size calculations are often inadequately reported, often with basic errors or omissions, and 
frequently based on assumptions that are inaccurate [6]. Usually four elements of information should 
be provided; type I error (conventionally 5% is the maximum accepted), power (usually a minimum of 
80% is expected), assumptions in the control group (response magnitude and standard deviation), and 
expected treatment effect. The sample size should be based on the primary outcome, should mirror 
how the primary outcome is to be analysed, and should contain sufficient detail for a statistician to 
replicate the calculation. Consider carefully whether the likely size of effect of the intervention is 
plausible and clinically relevant. Can the effect be ‘benchmarked’ against an intervention of known 
proven benefit (eg effect of Comprehensive Geriatric Assessment on mortality)? Is there data available 
on the minimum clinically important difference that can inform the effect size that is sought?  
Be explicit about how the outcomes were analysed; what tests were used, what statistics package was 
used, what statistical assumptions were tested prior to the analysis, and how missing data were 
handled. For most trials involving frail older people, missing data are inevitable. Last value carried 
forward approaches, or exclusion of those with missing data, often are not helpful and carry 
substantial risk of bias. Use of multiple imputation or mixed model approaches provide alternatives 
to minimise such biases.  
Related to this, state whether the analysis was done by intention to treat, modified intention to treat, 
or per-protocol, but state clearly what population was analysed, as these terms may cover a multitude 
of analytic choices. In general intention to treat approaches are to be preferred as the primary 
analysis, to reduce the risks of selection bias that come with adherence. Per-protocol analyses can 
however provide useful secondary data to help understanding of the potential magnitude of effect of 
‘sticking with’ an intervention.   
Box 3. 
Intention to treat approaches to data analysis are recommended as the primary statistical 
methodology.  
Per-protocol analyses can provide useful secondary data to help understand the potential 
magnitude of effect of an intervention. However this approach carries high risk of bias due to 
differential selection of subjects who adhere to treatment (or control group) allocation. 
 
 
The Results 
Describing the trial population 
When choosing what to include in the baseline descriptors table (which is usually Table 1 of any trial), 
authors should picture themselves as practising geriatricians reading the trial paper. What would they 
want to know? The baseline descriptors table needs to give sufficient information that the reader can 
judge whether the trial population was similar to that seen in clinical practice. This means not only 
giving age, sex, and details pertinent to the condition under study, but a range of information 
pertinent to the care and characterisation of older people. Suggested details to include in any clinical 
trial for older people are given in Table 1. As well as helping the reader understand the characteristics 
of the population under study, the baseline table is vital in showing whether the intervention and 
control groups were well matched for possible confounders. The statistical methods of summarising 
relevant descriptive data are well described by Pickering in a recent review article in this journal 6 . 
 
Participant flow through the trial 
A CONSORT flow diagram is a central part of reporting any trial, and is crucial to understanding the 
generalisability of the results 4 . Both numbers and reasons for dropouts at each stage of the trial 
should be provided, and numbers available for analysis given for each time-point. An often neglected 
part of the CONSORT diagram is information on how many potentially eligible participants were 
approached; this information not only helps the reader to decide how generalizable the results are (if 
only 2% of potentially eligible participants take part, generalisability is less than if 50% take part), but 
also helps future trialists plan how many people they will need to screen in order to recruit their target 
number. 
 
The Primary outcome 
Table 2 should usually contain the primary outcome analyses. The primary outcome is the most 
important part of the results – it is the main reason for having conducted the trial. It therefore follows 
that the space devoted to the primary outcome should be a significant part of the results. The primary 
outcome, and any pre-planned subgroup analyses, should be presented in this table. Sensitivity 
analyses often will be better placed in a supplementary on-line only appendix. The most helpful way 
to present outcome data varies , but in general, it is most informative to give summary values for each 
group at each time-point, and also between-group differences with 95% confidence intervals (i.e. 
treatment effect), which may be derived from a repeated measures analysis or given for a single, pre-
specified time-point. Giving information in both of these ways makes the size of the treatment effect 
clear to readers and facilitates the work of those undertaking systematic reviews and meta-analysis 7. 
 
Secondary outcomes 
These are by definition much less important than the primary outcome. In many trials, there is 
insufficient power to detect clinically relevant effects on secondary outcomes. Furthermore, if the 
study includes multiple secondary outcomes, statistically significant results will often be obtained by 
chance (type 1 statistical error). It therefore follows that fewer is often better when it comes to 
secondary outcomes – both in trial design and trial reporting. 
 
The author should consider what secondary outcomes are essential, and focus on reporting these in 
the main paper. Report the other secondary outcomes, but consider placing these in supplementary 
data. Avoid selective reporting of only the ‘most interesting’ or positive secondary outcome results. 
This leads to bias, potentially overstating the benefits from an intervention. In a similar, but related 
vein, be very cautious about post-hoc subgroup analyses. Such analyses are notoriously unreliable (for 
similar reasons of power and multiple testing described above), carry little credibility, and distract 
from what should be the main focus of a trial report. Such analyses are sometimes performed to find 
positive results in a trial which was negative; this is not appropriate. Age and Ageing welcomes trials 
with null results as long as they are well designed and the negative result is credible. 
 
Adverse events 
Adverse events are often poorly reported 8; such information is essential to appraise the potential 
harms of an intervention. Just as outcomes in trials involving older people need to capture potential 
benefits across a range of functional and organ domains, harms may occur in unexpected ways. Hence 
the reporting of adverse events needs to include harms across all organ systems and functional 
domains – not just those thought to be relevant to the intervention or condition under scrutiny. An 
example would be a trial of blood pressure medication – adverse effects on renal function would 
commonly be reported as a harm, but few trials of antihypertensives report falls as an adverse 
outcome 9, despite this clearly being highly relevant both to older people and to geriatricians. A further 
benefit of thorough reporting of adverse events is that they help the reader to judge whether the trial 
population resembles that seen in clinical practice. Older, frail people are often sick and have a high 
number of illness events in the real world. Trial populations with few adverse events are therefore 
likely to be rather fitter than the population seen in clinical practice, again questioning the 
generalisability of the results. A table of adverse events, including care home placement, 
hospitalisation and death, should usually be included in the supplementary information, with some 
comment on event rates in the main paper. 
 
 
 Presenting results and statistics 
A good principle to follow is that statistics are there to confirm what is obvious by inspecting the data. 
Giving statistical test results as p-values without clear simple summaries of effect of the intervention 
on the outcome measures is not adequate is this does not allow the reader to understand what the 
results mean in terms of clinical impact.   
Box 4. 
Reporting effect size and statistical significance: 
For each primary and secondary outcome, provide results for each group, and the estimated effect 
size (between group difference) and its precision (usually a 95% confidence interval). This should 
be accompanied by statistical significance (p-value) however reporting this on its own is not 
sufficient to enable interpretation of the clinical relevance of the results.  
 
 
 
Statistical methods should be described with enough detail that a knowledgeable reader with access 
to the original data could verify the reported results (www.icmje.org). They should follow an a-priori 
statistical analysis plan 10 . 
 
 
The discussion and conclusions 
It is good practice to structure the discussion section according to the advice in the CONSORT 
statement 4. This not only ensures coverage of all key aspects of the discussion, but also restricts the 
latitude for unsupported opinion and speculation. A summary of limitations is a key component. The 
discussion also needs to compare the findings with what others have reported, suggest reasons for 
any divergent results, and should also place the findings into their clinical context – in particular, it 
should comment on the generalisability and applicability (external validity).  Consider how the results 
might impact on clinical practice, health policy and future research. If one conclusion is that more 
research is required, be specific about what is needed – a bigger trial, a trial of a different intervention, 
or a trial in a different population?  
 
Avoid exaggerations and excessive speculation – there is the risk of both misleading the reader and 
loss of credibility of the report. Conclusions should be worded conservatively, and supported by the 
data given in the results. 
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Table 1: Key baseline characteristics for describing older populations included in clinical trials 
 
Attribute Notes / examples 
Age  Mean (or median) age in years and range of dispersion 
(SD, range).  
If predetermined subgroups eg >80 years of age then 
give numbers in subgroups. 
Sex Numbers of men and women 
Physical function Short Physical Performance Battery 11; grip strength 12; 
walking speed 13.  
Numbers using walking aids (sticks, walking frames) 
Cognition Abbreviated Mental Test score 14; Montreal Cognitive 
Assessment (MoCA); Mini-mental state examination 15. 
Basic and instrumental activities of daily 
living 
Barthel score 16; Functional Independence Measure; 
Instrumental Activities of Daily Living Scale 17 . 
Comorbid disease and its treatment Include all disease areas, not just those relevant to the 
direct focus of the trial intervention.  
Charlson comorbidity index, medication count 18; 
categories of medications. 
Frailty  Fried frailty phenotype 19; Rockwood frailty index 20; 
electronic Frailty Index 21 . 
May provide a useful summary of several of the above 
components 
Living arrangements  Numbers living alone.  
Numbers in standard housing, supported living, 
sheltered housing, care home. 
Formal help received (home help, district nurses). 
 
